Failure of BRCA1 dysfunction to alter ovarian cancer survival

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1196-1202

  Buller, Richard E ^a   Shahin, Mark S ^a   Geisler, John P ^a   Zogg, Melanie ^a   De Young, Barry R ^b   Davis, Charles S ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GERM LINE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHYLATION; ONCOGENE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC CELL;

BRCA1 PROTEIN; CASE-CONTROL STUDIES; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RNA, MESSENGER; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0036091069     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group experience
2. Prognostic factors in ovarian cancer
3. Analysis of prognostic factors in Stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
4. DNA ploidy in epithelial ovarian cancer: A new independent prognostic factor?
5. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
6. Epithelial ovarian carcinoma: Principles of primary surgery
7. Relationship of preoperative serum CA125 to survival in epithelial ovarian carcinoma
8. Prognostic value of pre and postoperative serum CA125 levels in ovarian cancer: New aspects and multivariate analysis
9. The prognostic significance of p53 tumor suppressor gene alternations in ovarian cancer
10. P53 mutations and expression in ovarian cancers: Correlation with overall survival
11. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1
12. Familial ovarian cancer
13. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
14. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1
15. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from Southern Sweden
16. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer
17. BRCA1 mutations in familial ovarian cancer
18. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer
19. Frequency of germ-line and somatic BRCA1 mutations in ovarian cancer
20. Frequency of BRCA1 dysfunction in ovarian cancer
21. BRCA1 promoter region hypermethylation in ovarian cancer: A population-based study
22. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer
23. An abundance of p53 null mutations in ovarian carcinoma
24. P53 mutations and microsatellite instability in ovarian cancer: Yin and Yang
25. Ovarian cancer BRCA1 mutation detection: Protein Truncation Test (PTT) outperforms single strand conformation polymorphism analysis (SSCP)
26. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
27. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc binding domains
28. Prognostic value of p53 genetic changes in colorectal cancer
29. P53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients
30. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
31. BRCA1, BRCA2, and DNA damage response: Collision or collusion?
32. Tables of the number of patients required in clinical trials using the logrank test